Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 11/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925485 | 0.91 | MEN1 (0.43) | CSF1RFLT1FLT3KDRTRPV1 | |
| SCHEMBL1924547 | 0.90 | ROCK2 (0.48) | CSF1RFLT1FLT3KDRTRPV1 | |
| SCHEMBL1924524 | 0.90 | KDM4E (0.45) | KDRPDGFRBTRPV1JAK2JAK3 | |
| SCHEMBL1924232 | 0.90 | MAPT (0.53) | KDRPDGFRBMAPTMEN1NPC1 | |
| SCHEMBL1924068 | 0.88 | MAPT (0.45) | KDRTRPV1JAK2JAK3MAPT | |
| SCHEMBL1924799 | 0.88 | BRAF (0.49) | CSF1RFLT1FLT3KDRPDGFRB | |
| SCHEMBL1924589 | 0.87 | CSF1R (0.58) | CSF1RFLT1FLT3KDRPDGFRB | |
| SCHEMBL1926655 | 0.87 | KDR (0.45) | KDRPDGFRBJAK3MAPTMEN1 | |
| SCHEMBL1924529 | 0.86 | MEN1 (0.60) | JAK3MAPTMEN1RAB9AKMT2A | |
| SCHEMBL1924479 | 0.86 | MAPT (0.55) | TRPV1JAK2JAK3MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856043-B1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2011-06-08 | — | — | EP | claimed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | claimed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | claimed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | WEE1, WEE2, FARS2 | CSF1R 791/4885FLT1 160/4885FLT3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.